Shares of RxSight, Inc. (NASDAQ:RXST - Get Free Report) have been assigned a consensus rating of "Hold" from the eleven research firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $6.94.
RXST has been the topic of a number of recent analyst reports. Weiss Ratings raised RxSight from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, November 12th. Wells Fargo & Company decreased their target price on shares of RxSight from $9.00 to $6.00 and set an "equal weight" rating for the company in a research report on Wednesday, November 4th. Jefferies Financial Group lowered their price target on shares of RxSight from $6.50 to $5.75 and set a "hold" rating for the company in a report on Tuesday, September 22nd. Bank of America dropped their price target on shares of RxSight from $6.50 to $5.50 and set an "underperform" rating on the stock in a research report on Tuesday, September 22nd. Finally, Piper Sandler reduced their price objective on shares of RxSight from $10.00 to $8.00 and set a "neutral" rating on the stock in a research note on Wednesday, November 4th.
View Our Latest Analysis on RXST
RxSight Stock Down 3.0%
Shares of RxSight stock opened at $4.47 on Friday. The stock has a market cap of $187.43 million, a price-to-earnings ratio of -3.49 and a beta of 1.21. RxSight has a twelve month low of $4.11 and a twelve month high of $13.22. The company's fifty day moving average is $4.90 and its 200 day moving average is $6.05.
RxSight (NASDAQ:RXST - Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.08). RxSight had a negative return on equity of 20.11% and a negative net margin of 43.80%. The company had revenue of $24.59 million for the quarter, compared to the consensus estimate of $27.19 million. As a group, equities analysts anticipate that RxSight will post -0.78 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, CFO Mark Wilterding sold 7,765 shares of RxSight stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $6.96, for a total transaction of $54,044.40. Following the completion of the transaction, the chief financial officer owned 25,049 shares of the company's stock, valued at $174,341.04. This trade represents a 23.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider M Kurtz sold 5,100 shares of the company's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $6.96, for a total transaction of $35,496.00. Following the sale, the insider directly owned 71,775 shares in the company, valued at $499,554. This trade represents a 6.63% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 16,947 shares of company stock valued at $117,951 in the last three months. 10.05% of the stock is owned by insiders.
Institutional Investors Weigh In On RxSight
Several institutional investors and hedge funds have recently made changes to their positions in RXST. BlackRock Inc. bought a new stake in RxSight in the second quarter worth approximately $27,910,000. Bank of America Corp DE boosted its holdings in shares of RxSight by 30.3% during the 1st quarter. Bank of America Corp DE now owns 1,210,039 shares of the company's stock worth $7,454,000 after buying an additional 281,426 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in shares of RxSight by 761.0% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,131,400 shares of the company's stock worth $6,969,000 after buying an additional 1,000,000 shares in the last quarter. Grandeur Peak Global Advisors LLC bought a new position in shares of RxSight during the 2nd quarter worth approximately $3,482,000. Finally, Goldman Sachs Group Inc. grew its position in shares of RxSight by 12.3% during the 3rd quarter. Goldman Sachs Group Inc. now owns 613,267 shares of the company's stock worth $3,005,000 after buying an additional 67,113 shares during the period. Institutional investors own 78.78% of the company's stock.
About RxSight
(
Get Free Report)
RxSight, Inc. is a medical technology company focused on products for cataract surgery and vision correction. Its main offering is the Light Adjustable Lens (LAL), an intraocular lens implanted during cataract surgery that can be adjusted after the procedure to refine a patient's vision. Adjustments are made with RxSight's Light Delivery Device, which uses ultraviolet light to change the lens's optical power. The company also provides related treatment-planning and patient-care products and services for clinicians using the LAL system.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider RxSight, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list.
While RxSight currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.